Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Girentuximab I-124 (Primary) ; Pazopanib; Sunitinib
- Indications Renal cell carcinoma
- Focus Diagnostic use
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 27 Dec 2016 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 27 Dec 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.